--- title: Available Clinical Trials for Cancer Treatment in Greater Philadelphia description: Available cancer clinical trials at Consultants in Medical Oncology and Hematology (CMOH) in Eastern Pennsylvania, including Broomall and Glen Mills. image: https://www.cmoh.org/hubfs/cmoh-cancer-clinical-trials.jpg --- [![Consultants in Medical Oncology and Hematology](https://www.cmoh.org/hubfs/cmoh-logo.svg) ![Consultants in Medical Oncology and Hematology](https://www.cmoh.org/hubfs/cmoh-logo.svg)](https://www.cmoh.org) [![Consultants in Medical Oncology and Hematology](https://www.cmoh.org/hubfs/cmoh-logo.svg)](https://www.cmoh.org) - [About Us](https://www.cmoh.org/about-cmoh) - [Referring Physicians](https://www.cmoh.org/referring-physicians) [Make an Appointment](https://www.cmoh.org/make-an-appointment) - Becoming a Patient - - [What to Expect](https://www.cmoh.org/what-to-expect) - [How We're Different](https://www.cmoh.org/how-were-different) - [Supportive Care](https://www.cmoh.org/supportive-care) - [Second Opinions](https://www.cmoh.org/second-opinions) - [Find a Physician](https://www.cmoh.org/our-team) - [Find a Location](https://www.cmoh.org/locations) - Current Patients - - [Patient Portal](https://patient.navigatingcare.com/) - [Billing and Insurance](https://www.cmoh.org/billing-insurance) - [Helpful Resources](https://www.cmoh.org/helpful-resources) - [Side Effect Management](https://www.cmoh.org/side-effect-management) - [Supportive Care](https://www.cmoh.org/supportive-care) - Our Team & Locations - - [Our Team](https://www.cmoh.org/our-team) - [Broomall Office](https://www.cmoh.org/locations) - [Glen Mills Office](https://www.cmoh.org/locations#glenmills) - [Newtown Square Office](https://www.cmoh.org/locations#newtownsquare) - How We Treat Cancer - - [Chemotherapy](https://www.cmoh.org/chemotherapy-for-cancer) - [Targeted Therapy](https://www.cmoh.org/targeted-therapy-for-cancer) - [Hormone Therapy](https://www.cmoh.org/hormone-therapy-for-cancer) - [Immunotherapy](https://www.cmoh.org/immunotherapy) - [Clinical Trials](https://www.cmoh.org/clinical-trials) - [Supportive Care](https://www.cmoh.org/supportive-care) - Cancers & Blood Disorders - - [Breast Cancer](https://www.cmoh.org/education#!/content/ZGrNJCg6/types-of-breast-cancer) - [Lung Cancer](https://www.cmoh.org/lung-cancer) - [Colorectal Cancer](https://www.cmoh.org/colorectal-cancer) - [Lymphoma](https://www.cmoh.org/lymphoma) - [Leukemia](https://www.cmoh.org/leukemia) - [About Us](https://www.cmoh.org/about-cmoh) - [Referring Physicians](https://www.cmoh.org/referring-physicians) [Make an Appointment](https://www.cmoh.org/make-an-appointment) # Available Clinical Trials ##### [Clinical Trials Overview](https://www.cmoh.org/clinical-trials) ##### [Clinical Trial FAQs](https://www.cmoh.org/clinical-trials/clinical-trial-faqs) ##### [Clinical Trial Phases](https://www.cmoh.org/clinical-trials/clinical-trial-phases) ##### [Clinical Trial Locations](https://www.cmoh.org/clinical-trials/clinical-trial-locations) ##### [Clinical Trial Resources](https://www.cmoh.org/clinical-trials/clinical-trial-resources) ##### [Clinical Trial Myths](https://www.cmoh.org/clinical-trials/clinical-trial-myths) Throughout the last century, the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. CMOH's physicians have embraced clinical cancer research as a critical component of community-based oncology care. Through a partnership with The US Oncology Network.  You do not have to leave the area to receive premier cancer care.  If you are interested in learning more about our research program, please contact [215-658-7240](tel:2156587240) or visit: [usoncology.com/researchparticipantinformation/](https://usoncology.com/researchparticipantinformation/)  ## CMOH Open Trials ##### as of June 2024 Please contact Maureen Lisowski for patient screening or any other available information.  ​[Maureen.Lisowski@usoncology.com](mailto:Maureen.Lisowski@usoncology.com) 610-585-6287     **Breast** **17079-**FLEX**-NCT03053193-**Agendia MammaPrint, Blueprint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry - **Stage(s)** – I, II, III **23189-** DYNASTY-Breast02-DB-1303-O-3002- **NCT06018337-**IQVIA Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002) - **Phase** – III - **Stage(s)** – Advanced or Metastatic - **Line of Therapy** – 1st, 2nd - **Investigational Drug** – DB-1303 - **Drug Class** – Antibody Drug Conjugate - **Mechanism of Action** – Third-generation topoisomerase-1 inhibitor-based - **Biomarker(s)** – HER2-low expression --- **Leukemia** **18263- STAR-**BGB-3111-215**-NCT04116437-**Beigene Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Acalabrutinib - **Phase** – II - **Stage(s)** – Any - **Line of Therapy** – 2+ - **Investigational Drug** – Zanubrutinib (BGB-3111) - **Drug Class** – BTK Inhibitor - **Mechanism of Action** – Forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity.   --- **Lung** **21498-**RAMP 203**-**VS-6766-203-**NCT05074810-**Verastem Inc Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) - **Phase** – II - **Stage(s)** – III, IV - **Line of Therapy** – 2nd, 3rd - **Investigational Drug** – Avutometinib (VS-6766) - **Drug Class** – MEK/RAF TKI - **Mechanism of Action** – Blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. - **Biomarker(s)** – KRAS G12C **22198- STAR-**FURMO-004-**NCT05607550-**Arrivent Biopharma, Inc Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations - **Phase** – III - **Stage(s)** – III, IV - **Line of Therapy** – 1st - **Investigational Drug** – Furmonertinib (AST2818) - **Drug Class** – EGFR TKI - **Mechanism of Action** – Irreversibly inhibits both EGFR sensitizing and T790M resistant mutations. - **Biomarker(s)** – EGFR exon 20 insertion **23256-STAR-**FURMO-002-**NCT05364073-STAR-**Arrivent Biopharma, Inc Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURMO-002) - **Phase** – I - **Stage(s)** – All - **Line of Therapy** –2+ - **Investigational Drug** – Furmonertinib (AST2818) - **Drug Class** – EGFR HER2 TKI - **Mechanism of Action**- an epidermal growth factor Receptor (EGFR) tyrosine Kinase inhibitor (TKI) Irreversibly inhibits both EGFR sensitizing and T790M resistant mutations. - **Biomarker(s)** – EGFR or HER2 Mutations   --- **Solid Tumor** **19151- STAR-**849-001**-NCT03785249-**Mirati Therapeutics, Inc Adagrasib (MRTX849) in Patients with Advanced Solid Tumors (No CRC, appendiceal, or NSCLC) with KRAS G12C Mutation - **Phase** – I/II - **Stage(s)** – III, IV - **Line of Therapy** – All - **Investigational Drug** – Adagrasib (MRTX849) - **Drug Class** – KRAS G12C Inhibitor - **Mechanism of Action** – Selectively and irreversibly binds to the KRAS G12C locking it in the inactive GDP bound state. - **Biomarker(s)** – KRAS G12C **20186-**Tapistry- BO41932-**NCT04589845-**Roche Laboratories, Inc Tumor-agnostic Precision Immuno-oncology and somatic targeting rational for you - **Phase** – II - **Stage(s)** – III, IV - **Line of Therapy** – All - **Investigational Drug** –Entrectinib - **Drug Class** – TKIs - **Mechanism of Action** – *Entrectinib:* binds to and blocks NTRK - **Biomarker(s)** –NTRK 1/2/3   **22123-** **STAR-**1403-0011**-NCT05512377**-**STAR-**Boehringer Ingelheim BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, & other select solid tumors - **Phase** – II - **Stage(s)** – III, IV - **Line of Therapy** – 2+ - **Investigational Drug** – Brigimadlin (BI 907828) - **Drug Class** – MDM2-p53 Antagonist - **Mechanism of Action** – Inhibits the interaction between the p53 and MDM2 proteins. - **Biomarker(s)** – MDM2 **20412- STAR-**LIBRETTO-432-J2G-MC-JZJX-**NCT04819100**-**STAR-**Eli Lilly Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC - **Phase** – III - **Stage(s)** – I, II, III - **Line of Therapy** – 2+ - **Investigational Drug** – Selpercatinib (LY3527723) - **Drug Class** – RET Kinase Inhibitor - **Mechanism of Action** – Selectively binds to and targets various RET mutants and RET-containing fusion. - **Biomarker(s)** – RET   **21318-** **STAR-**BO42777**-NCT05170204-****STAR-**Roche Laboratories, Inc Alectinib Compared with Durvalumab in Patients with Locally Advanced, Unresectable, Stage III ALK Positive Non-Small Cell Lung Cancer after Concurrent or Sequential Chemoradiotherapy (BO42777) - **Phase** – III - **Stage(s)** – III - **Line of Therapy** – 2+ - **Investigational Drug** – Alectinib (RO5424802) - **Drug Class** – ALK TKI - **Mechanism of Action** – Inhibits ALK and RET proteins by preventing their phosphorylation. - **Biomarker(s)** – ALK  **22311:** DATA- Hh-Prt-0001- **NCT05435066-**Harbinger Health Collection of Blood and Tissue Samples from Cancer Subjects For Validation Of A Novel Blood-Based Multi-Cancer Screening Test COHORTS OPEN: Lung – NSC & SC Colon & Rectum Head and Neck Pancreas Liver Kidney Urinary Bladder     ![calendar-check-solid-1](https://www.cmoh.org/hubfs/calendar-check-solid-1.svg) #### Request an appointment with our cancer research experts in Broomall, Newtown Square, or Glen Mills, PA. [Make an Appointment](https://www.cmoh.org/make-an-appointment) [![cmoh-logo](https://www.cmoh.org/hubfs/cmoh-logo.svg)](https://www.cmoh.org) - [Contact](https://www.cmoh.org/contact) - [Privacy Practices](https://www.cmoh.org/hubfs/PDF%20Downloads/npp_201909.pdf) - [Find a Location in PA](https://www.cmoh.org/locations) - [Referring Physicians](https://www.cmoh.org/referring-physicians) ©2026 Copyright Consultants in Medical Oncology and Hematology, PC and Oncology Management Services. OPMCH® and Oncology Patient Centered Medical Home® are registered trademarks of Oncology Management Services. - -